Q-omics provides the consensus-scored GNRHR2 profile across patient tissues and cancer cell-line models. GNRHR2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GNRHR2 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, GNRHR2 RNA expression shows 20,515 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, and ACC as cancer lineages where GNRHR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNRHR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNRHR2 survival associations across molecular data types. GNRHR2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNRHR2 RNA expression–survival associations across cancer types. High GNRHR2 expression shows unfavorable associations in LIHC, ACC and KICH, but favorable associations in HNSC, LUAD and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GNRHR2 RNA expression.
This table summarizes GNRHR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GNRHR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNRHR2 shows lower tumor expression in KIRC and THCA and higher tumor expression in LIHC, LUSC, CHOL and BLCA. The LIHC box plot shows higher GNRHR2 RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p < 0.001).
This table shows molecular features associated with GNRHR2 in patient tissues and cancer cell lines. In patient samples, GNRHR2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNRHR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
